BR112021024532A2 - Terapia combinada anticâncer - Google Patents

Terapia combinada anticâncer

Info

Publication number
BR112021024532A2
BR112021024532A2 BR112021024532A BR112021024532A BR112021024532A2 BR 112021024532 A2 BR112021024532 A2 BR 112021024532A2 BR 112021024532 A BR112021024532 A BR 112021024532A BR 112021024532 A BR112021024532 A BR 112021024532A BR 112021024532 A2 BR112021024532 A2 BR 112021024532A2
Authority
BR
Brazil
Prior art keywords
anticancer therapy
combination anticancer
combination
therapy
inhibitor
Prior art date
Application number
BR112021024532A
Other languages
English (en)
Inventor
Hans Hofmann Marco
Michael Gmachl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112021024532A2 publication Critical patent/BR112021024532A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

terapia combinada anticâncer. a presente invenção refere-se a terapias anticâncer compreendendo o uso de um inibidor de sos1 em combinação com um inibidor de mek, cada um deles estando descrito neste pedido.
BR112021024532A 2019-06-19 2020-06-17 Terapia combinada anticâncer BR112021024532A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181360 2019-06-19
PCT/EP2020/066839 WO2020254451A1 (en) 2019-06-19 2020-06-17 Anticancer combination therapy

Publications (1)

Publication Number Publication Date
BR112021024532A2 true BR112021024532A2 (pt) 2022-05-24

Family

ID=66999660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024532A BR112021024532A2 (pt) 2019-06-19 2020-06-17 Terapia combinada anticâncer

Country Status (12)

Country Link
US (1) US20220249492A1 (pt)
EP (1) EP3986408A1 (pt)
JP (1) JP2022537044A (pt)
KR (1) KR20220024191A (pt)
CN (1) CN114375202A (pt)
AU (1) AU2020296914A1 (pt)
BR (1) BR112021024532A2 (pt)
CA (1) CA3142239A1 (pt)
CL (1) CL2021003353A1 (pt)
MX (1) MX2021016137A (pt)
TW (1) TW202114683A (pt)
WO (1) WO2020254451A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829487B2 (en) 2017-12-21 2020-11-10 Boehringer Ingelheim International Gmbh Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
MX2023008460A (es) 2021-01-19 2023-09-12 Lupin Ltd Combinaciones farmacéuticas de inhibidores de sos1 para el tratamiento y/o prevención del cáncer.
CN113200981A (zh) * 2021-02-10 2021-08-03 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
US20220324862A1 (en) * 2021-03-31 2022-10-13 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
CN117337297A (zh) * 2021-05-12 2024-01-02 锐新医药公司 Sos1抑制剂与mtor抑制剂用以治疗癌症的用途
WO2023011540A1 (zh) * 2021-08-03 2023-02-09 苏州信诺维医药科技股份有限公司 稠环化合物、药物组合物及其应用
CN115417868B (zh) * 2021-09-13 2024-04-02 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2023041049A1 (zh) * 2021-09-17 2023-03-23 江苏先声药业有限公司 作为sos1抑制剂的杂环化合物及其用途
CN115057847B (zh) * 2022-07-26 2024-01-26 山东百启生物医药有限公司 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405006PA (en) 2012-03-14 2014-10-30 Lupin Ltd Heterocyclyl compounds as mek inhibitors
WO2018115380A1 (en) * 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
US10829487B2 (en) 2017-12-21 2020-11-10 Boehringer Ingelheim International Gmbh Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors

Also Published As

Publication number Publication date
JP2022537044A (ja) 2022-08-23
US20220249492A1 (en) 2022-08-11
EP3986408A1 (en) 2022-04-27
AU2020296914A1 (en) 2021-12-23
TW202114683A (zh) 2021-04-16
KR20220024191A (ko) 2022-03-03
CN114375202A (zh) 2022-04-19
CA3142239A1 (en) 2020-12-24
MX2021016137A (es) 2022-02-21
CL2021003353A1 (es) 2022-09-30
WO2020254451A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
BR112021024532A2 (pt) Terapia combinada anticâncer
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
UY33866A (es) Terapia anticancer
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
BR112018073384A2 (pt) polinucleotídeos moduladores
CY1122283T1 (el) Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
TWD189837S (zh) 定序儀之前面板
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
BR112018009511A2 (pt) derivados de pirazolo pirimidina
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
BR112016000903A2 (pt) anticorpos
MX2016013218A (es) Molecula de unión al antígeno trifuncional.
EP4233840A3 (en) Combinations of linagliptin and metformin
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA202191556A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
SV2019005822A (es) Metodos para tratar el cáncer de próstata
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]